Immunome Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	653.48	143.35	98.68	20.32	49.23
Short-Term Investments	-	73.95	39.46	-	-
Cash & Short-Term Investments	653.48	217.3	138.14	20.32	49.23
Cash Growth	200.72%	57.30%	579.73%	-58.72%	23.80%
Other Current Assets	7.3	4.04	6.56	2.33	7.41
Total Current Assets	660.78	221.34	144.7	22.65	56.64
Net Property, Plant & Equipment	17.61	14.39	3.64	0.97	0.86
Other Long-Term Assets	4.8	4.51	0.2	0.43	0.43
Total Assets	683.19	240.24	148.54	24.05	57.93
Accounts Payable	3.34	14.19	3.31	2.4	3.08
Accrued Expenses	41.65	33.18	8.03	4.93	6.65
Unearned Revenue	-	6.94	10.49	-	-
Total Current Liabilities	44.99	54.31	21.83	7.33	9.73
Long-Term Leases	3.86	4.77	1.34	-	-
Other Long-Term Liabilities	-	-	5.49	0.06	0.01
Total Long-Term Liabilities	3.86	4.77	6.83	0.06	0.01
Total Liabilities	48.85	59.08	28.66	7.39	9.74
Common Stock	0.01	0.01	0	0	0
Additional Paid-in Capital	1,362	696.87	342.66	132.65	127.29
Accumulated Other Comprehensive Income	-	0.06	0.02	-	-
Retained Earnings	-728.16	-515.77	-222.81	-116	-79.11
Shareholders' Equity	634.34	181.17	119.88	16.65	48.19
Total Liabilities & Equity	683.19	240.24	148.54	24.05	57.93
Total Debt	3.86	4.77	1.34	0	0
Net Cash (Debt)	649.63	212.53	136.8	20.32	49.23
Net Cash Growth	205.66%	55.36%	573.14%	-58.72%	25.76%
Net Cash Per Share	7.44	3.62	6.89	1.68	4.27
Book Value	634.34	181.17	119.88	16.65	48.19
Book Value Per Share	7.26	3.09	6.04	1.37	4.18
Tangible Book Value	634.34	181.17	119.88	16.65	48.19
Tangible Book Value Per Share	7.26	3.09	6.04	1.37	4.18

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q